A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2014-09-01

Summary

A Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC).

• Phase: Phase 2

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Veliparib